Advertisement

Picture EBD Group World of Partnering Opportunities 650x100px
Organisation › Details

Affimed N.V. (Nasdaq: AFMD)

Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s innate cell engagers (ICE®) enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. ICE® are generated on the Company’s proprietary ROCK® platform which predictably generates customized molecules that leverage the power of innate immune cells to destroy tumor cells. A number of ICE® molecules are in clinical development, being studied as mono- or combination therapy. Headquartered in Mannheim, Germany, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by the bold vision to stop cancer from ever derailing patients’ lives. *

 

Period Start 2014-09-17 existent
  Group Affimed (Group)
  Predecessor Affimed Therapeutics AG
Products Industry MAb, human, fully
  Industry 2 TandAb bispecific antibody
Persons Person Fischer, Wolfgang (Affimed 201709– COO before Sandoz Biopharmaceuticals + Novartis)
  Person 2 Harstrick, Andreas (Affimed 202204 CMO)
     
Region Region Mannheim
  Country Germany
  Street 2 Gottlieb-Daimler-Str.
  City 68165 Mannheim
  Tel +49-621-56003-0
    Address record changed: 2024-04-05
     
Basic data Employees D: 101 to 500 (2021-12-31)
  Currency EUR
  Annual sales 41,353,000 (revenue, consolidated (2022) 2022-12-31)
  Profit -86,004,000 (2022-12-31)
  Cash 190,286,000 (2022-12-31)
     
    * Document for »About Section«: Affimed N.V.. (3/6/24). "Press Release: Affimed Announces 1-for-10 Reverse Stock Split". Mannheim.
     
   
Record changed: 2024-04-07

Advertisement

Picture Berlin Partner Top News Captain T Cell Therapies 650x200px

More documents for Affimed (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group World of Partnering Opportunities 650x300px




» top